BTIG analyst Marie Thibault raised the firm's price target on Edwards Lifesciences to $110 from $100 and keeps a Buy rating on the shares. Edwards Lifesciences, the firm's 2026 Top Pick, has outperformed its large-cap MedTech peers in recent weeks, and its sales and EPS growth profile are likely to outpace the peer group, the analyst tells investors in a research note. The recently proposed CMS national coverage determination will be a positive tailwind for the company's TAVR segments for years to come, BTIG adds.
